5Cezário RC,Duarte De Morais L,Ferreira JC. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital[J].Enfermedades infecciosas y microbiologia clinica,2009,(05):269-274.
6Tam VH,Chang KT,LaRocco MT. Prevalence,mechanisms and risk factors of carbapenem resistance in bloodstream isolated of Pseudomonas aeruginosa[J].Diagn Microbiol Infeat Dis,2007,(03):309-314.
9Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing; twentieth informational supplement.Wayne:Clinical and Laboratory Standards Institute,2010.
10U.S.Food and Drug Administration.Tygacil (tigecycline) for injection.[2010-04-20].http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821 s0161bl.pdf.
6Salgado CD,Ogragy N. Farr. Bin. Prevention and control of anti- microbial resistan infections in intensive care patients. Crit Care Med,2005,33(10) :2373-2382.
7GARRITY G. Bergey’s manual of systematic bacteriology [M]. Vol 3. New York: Springer-Verlag New York Inc, 2009: 594-560.
8Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing [M]. M100- S22. USA: CLSI, 2012.
9SHEPARD B D, GILMORE M S. Antibiotic-resistant enteroeoeeus: the mechanisms and dynamics of drug introduction and resistance [J]. Microbes Infect, 2002, 4(2): 215-224.
10KNOLL B M, HELLMANN M, KOTTON C N. Vancomycin-resistant Enterococcus faecium meningitis in adults: Case series and review of the literature [J]. Scand J Infect Dis, 2013, 45(2): 131-139.
